7,856 Shares in Pfizer Inc. (NYSE:PFE) Acquired by Mosaic Financial Group LLC

Mosaic Financial Group LLC purchased a new stake in Pfizer Inc. (NYSE:PFE) during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 7,856 shares of the biopharmaceutical company’s stock, valued at approximately $208,000.

Other hedge funds have also recently bought and sold shares of the company. Retirement Wealth Solutions LLC bought a new stake in shares of Pfizer in the 4th quarter worth about $26,000. Rialto Wealth Management LLC acquired a new position in Pfizer in the fourth quarter valued at about $26,000. Kohmann Bosshard Financial Services LLC bought a new stake in Pfizer during the fourth quarter worth about $28,000. Noble Wealth Management PBC bought a new stake in Pfizer during the fourth quarter worth about $31,000. Finally, Curio Wealth LLC acquired a new stake in shares of Pfizer during the fourth quarter worth approximately $32,000. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, Director Ronald E. Blaylock purchased 19,457 shares of the stock in a transaction dated Thursday, February 13th. The stock was bought at an average cost of $25.65 per share, with a total value of $499,072.05. Following the purchase, the director now directly owns 27,707 shares in the company, valued at $710,684.55. The trade was a 235.84 % increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at this link. Company insiders own 0.06% of the company’s stock.

Pfizer Trading Up 0.6 %

Shares of NYSE PFE opened at $25.36 on Tuesday. Pfizer Inc. has a fifty-two week low of $24.48 and a fifty-two week high of $31.54. The firm has a market capitalization of $143.80 billion, a P/E ratio of 17.98, a P/E/G ratio of 0.64 and a beta of 0.61. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The company’s 50 day simple moving average is $26.05 and its 200 day simple moving average is $26.88.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, beating analysts’ consensus estimates of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The company had revenue of $17.76 billion for the quarter, compared to the consensus estimate of $17.26 billion. During the same quarter in the prior year, the business posted $0.10 EPS. The firm’s quarterly revenue was up 24.7% on a year-over-year basis. On average, analysts predict that Pfizer Inc. will post 2.95 EPS for the current year.

Analyst Ratings Changes

PFE has been the topic of several recent analyst reports. Bank of America restated a “neutral” rating and set a $29.00 price target on shares of Pfizer in a research report on Tuesday, December 10th. Guggenheim restated a “buy” rating on shares of Pfizer in a report on Tuesday, March 18th. UBS Group lowered their target price on Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a research note on Wednesday, January 8th. Hsbc Global Res upgraded shares of Pfizer to a “strong-buy” rating in a research report on Monday, March 10th. Finally, Truist Financial lowered their price objective on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a research report on Wednesday, December 18th. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating, six have given a buy rating and three have issued a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $31.92.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.